Key takeaway: Cipla Limited's Q2FY27 investor presentation highlights consistent sequential growth in revenue and EBITDA, with revenue reaching INR 7,404 Cr and EBITDA at INR 1,388 Cr. The company reported its highest-ever quarterly revenue of INR 3,516 Cr in the period. Key business segments include One India (48% of revenue), North America (22%), One Africa (16%), and Emerging Markets & Europe (13%). Strategic initiatives include receiving U.S. FDA approval for gAdvair Diskus and expanding its portfolio with new launches like Yurpeak and Rizontem. The company also emphasized its oncology-focused biosimilars portfolio through partnerships with Qilu Pharmaceutical and CTTQ. In South Africa, private business revenue reached ZAR 1,294 Mn, with growth outpacing the market. ESG progress includes achieving 77% renewable electricity share in India and advancing toward water neutrality. Financials show a consolidated profit of INR 878 Cr for the period. The presentation includes forward-looking statements with associated risks and uncertainties.

Key takeaway: Cipla Limited reported its highest-ever Q1 revenue of INR 7,100 crores for the quarter ended June 2026, reflecting a 12% year-on-year growth in its One India business. Management highlighted strong performance across key therapies, particularly in the branded prescription segment, which grew by 15.4%. The company launched several new products, including in the respiratory and obesity segments, and maintained its leadership in the U.S. Albuterol MDI market with a 21% market share. Financially, Cipla reported a 2% year-on-year revenue growth, with an EBITDA margin of 16.7%. Management noted that operating expenses increased due to planned investments in product launches. The company aims to sustain growth in its chronic therapies and maintain a strong presence in North America and South Africa, despite challenges in the tender business. The earnings call concluded with a Q&A session addressing various operational and financial queries.

Key takeaway: Cipla Limited reported its highest-ever quarterly revenue of INR 7,119 crore for Q1FY27, reflecting a year-on-year increase from INR 6,957 crore. The company's EBITDA was INR 1,192 crore, with a margin of 16.7%, down from 25.6% in the previous year. Profit After Tax (PAT) was INR 789 crore, compared to INR 1,298 crore in Q1FY26, resulting in a PAT margin of 11.1%. The revenue breakdown showed One India contributing 48%, North America 22%, One Africa 14%, and Emerging Markets & Europe 14%. Cipla maintained its #2 rank in overall chronic therapies, with a chronic mix improvement to 60.4%. The company launched several new products, including gVentolin in the U.S. market. Cipla's South Africa operations showed strong growth, with private business revenue reaching ZAR 906 million for Q1FY27. The presentation also highlighted progress on various ESG goals.

Key takeaway: Cipla Limited's Q4 FY26 earnings conference call highlighted significant achievements across its business segments. Management reported that the company surpassed INR 12,500 crores in revenues in India, marking a 15% year-on-year growth for the quarter. The North America segment generated USD 155 million in quarterly revenue, bolstered by the approval of a generic Ventolin. The One Africa business grew 14% year-on-year, while EMEU operations exceeded USD 400 million in revenue. Management emphasized a strong focus on R&D, with plans for 40-50 product filings over the next three years. Financially, the company reported a quarterly revenue of INR 6,541 crores and an EBITDA margin of 15.2%. Management set a goal for EBITDA margins to range between 18.5% and 20% for FY27, excluding contributions from Lanreotide. The call concluded with a Q&A session addressing various operational and strategic queries.

Key takeaway: Cipla Limited reported its investor presentation for Q4 FY26, highlighting its highest-ever yearly revenue of INR 28,163 Cr, despite facing multiple headwinds. The presentation detailed a revenue of INR 6,541 Cr for Q4 FY26, with a year-on-year decline in EBITDA and PAT, which stood at INR 997 Cr and INR 555 Cr, respectively. Management noted double-digit growth across three segments, particularly in chronic therapies. The company achieved a significant milestone with the approval of the first AB-rated gVentolin. Cipla maintained a strong net cash position exceeding $1 billion, which management indicated would support future growth investments. The presentation also emphasized Cipla's commitment to sustainability, achieving notable progress in its ESG goals, including a significant reduction in emissions and water neutrality. Overall, the document provided a comprehensive overview of Cipla's financial performance and strategic initiatives.